Telaprevir therapy, renal impairment, and their effects on the pharmacokinetics of tenofovir in HIV/hepatitis C virus coinfected patients

AIDS. 2014 Jan 14;28(2):285-7. doi: 10.1097/QAD.0000000000000088.
No abstract available

Publication types

  • Case Reports
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenine / analogs & derivatives*
  • Adenine / pharmacokinetics
  • Adult
  • Antiviral Agents / administration & dosage
  • Antiviral Agents / adverse effects*
  • Antiviral Agents / pharmacokinetics*
  • HIV Infections / drug therapy*
  • Hepatitis C / drug therapy*
  • Humans
  • Kidney Diseases / chemically induced*
  • Male
  • Oligopeptides / administration & dosage
  • Oligopeptides / adverse effects*
  • Organophosphonates / pharmacokinetics*
  • Tenofovir

Substances

  • Antiviral Agents
  • Oligopeptides
  • Organophosphonates
  • telaprevir
  • Tenofovir
  • Adenine